TNFα cooperates with IFN-γ to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Liu, Feiyan ^a,b   Hu, Xiaolin ^b   Zimmerman, Mary ^b   Waller, Jennifer L ^b   Wu, Ping ^a   Hayes Jordan, Andrea ^c   Lev, Dina ^c   Liu, Kebin ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CASPASE 8; GAMMA INTERFERON; PROTEIN BCL XL; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SURVIVIN; BCL2L1 PROTEIN, MOUSE; PROTEIN BCL X; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CELL SPECIFICITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENTIATION; EX VIVO STUDY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTOPOIESIS; METASTASIS POTENTIAL; MONOTHERAPY; MOUSE; NONHUMAN; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; ANIMAL; BLOOD; COLON TUMOR; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; CASPASE 8; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; INTERFERON-GAMMA; MICE; NEOPLASM METASTASIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79251576481     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016241     Document Type: Article

References (73)

1. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, et al. (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27: 3677-3683.
2. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22: 329-360.
3. Karlsson M, Marits P, Dahl K, Dagoo T, Enerback S, et al. (2010) Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol 17: 1747-1757.
4. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357.
5. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
6. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, et al. (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-2666.
7. Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, et al. (2009) Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 69: 2685-2693.
8. Strater J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, et al. (2005) Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 54: 661-665.
9. Jalving M, de Jong S, Koornstra JJ, Boersma-van Ek W, Zwart N, et al. (2006) TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res 12: 4350-4356.
10. Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798.
11. Holoch PA, Griffith TS (2009) TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 625: 63-72.
12. Kim SH, Ricci MS, El-Deiry WS (2008) Mcl-1: a gateway to TRAIL sensitization. Cancer Res 68: 2062-2064.
13. Xu J, Zhou JY, Wei WZ, Wu GS (2010) Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 5: e10226.
14. Kaler P, Galea V, Augenlicht L, Klampfer L (2010) Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1b-dependent stabilization of Snail in tumor cells. PLoS One 5: e11700.
15. Rosato RR, Almenara JA, Coe S, Grant S (2007) The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 67: 9490-9500.
16. Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, et al. (2007) Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res 67: 6987-6994.
17. Shankar S, Ganapathy S, Srivastava RK (2008) Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res 14: 6855-6866.
18. Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, et al. (2009) Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther 8: 1596-1605.
19. Voelkel-Johnson C, Hannun YA, El-Zawahry A (2005) Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein. Mol Cancer Ther 4: 1320-1327.
20. Yodkeeree S, Sung B, Limtrakul P, Aggarwal BB (2009) Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. Cancer Res 69: 6581-6589.
21. Bauer JA, Lupica JA, Schmidt H, Morrison BH, Haney RM, et al. (2007) Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling. PLoS One 2: e1313.
22. Chawla-Sarkar M, Bauer JA, Lupica JA, Morrison BH, Tang Z, et al. (2003) Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem 278: 39461-39469.
23. Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, et al. (2006) The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 11: 1175-1193.
24. Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD, et al. (2008) Involvement of c- FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther 7: 3556-3565.
25. Kauh J, Fan S, Xia M, Yue P, Yang L, et al. (2010) c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One 5: e10376.
26. Xu J, Zhou JY, Wu GS (2006) Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res 66: 10092-10099.
27. Darvas K, Rosenberger S, Brenner D, Fritsch C, Gmelin N, et al. (2010) Histone deacetylase inhibitor-induced sensitization to TNFa/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression. Int J Cancer 127: 1384-1392.
28. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, et al. (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193: 661-670.
29. Tekautz TM, Zhu K, Grenet J, Kaushal D, Kidd VJ, et al. (2006) Evaluation of IFN-c effects on apoptosis and gene expression in neuroblastoma-preclinical studies. Biochim Biophys Acta 1763: 1000-1010.
30. Zhou Y, Weyman CM, Liu H, Almasan A, Zhou A (2008) IFN-c induces apoptosis in HL-60 cells through decreased Bcl-2 and increased Bak expression. J Interferon Cytokine Res 28: 65-72.
31. Ahn EY, Pan G, Vickers SM, McDonald JM (2002) IFN-c upregulates apoptosis-related molecules and enhances Fas-mediated apoptosis in human cholangiocarcinoma. Int J Cancer 100: 445-451.
32. Lissat A, Vraetz T, Tsokos M, Klein R, Braun M, et al. (2007) Interferon-c sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosisinducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J Pathol 170: 1917-1930.
33. Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, et al. (2009) Histone deacetylase inhibitors cooperate with IFN-c to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 28: 3097-3110.
34. Elrod HA, Fan S, Muller S, Chen GZ, Pan L, et al. (2010) Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PLoS One 5: e12178.
35. White-Gilbertson S, Mullen T, Senkal C, Lu P, Ogretmen B, et al. (2009) Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene 28: 1132-1141.
36. Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9: 361-371.
37. Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, et al. (2007) Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res 67: 5880-5888.
38. Kamat AM, Tharakan ST, Sung B, Aggarwal BB (2009) Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kB and upregulation of TRAIL receptors. Cancer Res 69: 8958-8966.
39. Sinicrope FA, Penington RC (2005) Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol Cancer Ther 4: 1475-1483.
40. Mendoza FJ, Ishdorj G, Hu X, Gibson SB (2008) Death receptor-4 (DR4) expression is regulated by transcription factor NF-kB in response to etoposide treatment. Apoptosis 13: 756-770.
41. Gagiannis S, Muller M, Uhlemann S, Koch A, Melino G, et al. (2009) Parathyroid hormone-related protein confers chemoresistance by blocking apoptosis signaling via death receptors and mitochondria. Int J Cancer 125: 1551-1557.
42. Sung B, Ravindran J, Prasad S, Pandey MK, Aggarwal BB (2010) Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem 285: 35418-35427.
43. Tillman DM, Izeradjene K, Szucs KS, Douglas L, Houghton JA (2003) Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosisinducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res 63: 5118-5125.
44. Panner A, Crane CA, Weng C, Feletti A, Parsa AT, et al. (2009) A novel PTENdependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res 69: 7911-7916.
45. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, et al. (2009) Small molecule xIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 69: 2425-2434.
46. Ammann JU, Haag C, Kasperczyk H, Debatin KM, Fulda S (2009) Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kB inhibition. Int J Cancer 124: 1301-1311.
47. Ndozangue-Touriguine O, Sebbagh M, Merino D, Micheau O, Bertoglio J, et al. (2008) A mitochondrial block and expression of xIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 27: 6012-6022.
48. Seol DW, Li J, Seol MH, Park SY, Talanian RV, et al. (2001) Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res 61: 1138-1143.
49. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, et al. (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11(Suppl 1): S86-96.
50. Izeradjene K, Douglas L, Delaney AB, Houghton JA (2004) Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of Fas-associated death domain and procaspase-8 to the death-inducing signaling complex. Cancer Res 64: 8036-8044.
51. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, et al. (2001) Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 61: 1645-1651.
52. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A (2007) Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 6: 2591-2599.
53. Fulda S, Debatin KM (2006) 5-Aza-29-deoxycytidine and IFN-c cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 25: 5125-5133.
54. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, et al. (2004) IKKb links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296.
55. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M (2004) Inhibition of NF-kB in cancer cells converts inflammation- induced tumor growth mediated by TNFa to TRAIL-mediated tumor regression. Cancer Cell 6: 297-305.
56. Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA (2010) Inhibition of NF-kB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem 285: 19162-19172.
57. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, et al. (2009) A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16: 295-308.
58. O'Mahony A, Lin X, Geleziunas R, Greene WC (2000) Activation of the heterodimeric IkB kinase alpha (IKKa)-IKKb complex is directional: IKKa regulates IKKb under both basal and stimulated conditions. Mol Cell Biol 20: 1170-1178.
59. van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, et al. (2009) Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One 4: e6982.
60. Haynes NM, Hawkins ED, Li M, McLaughlin NM, Hammerling GJ, et al. (2010) CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J Immunol 185: 532-541.
61. Ravi R, Fuchs EJ, Jain A, Pham V, Yoshimura K, et al. (2006) Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res 66: 1730-1739.
62. Lippa MS, Strockbine LD, Le TT, Branstetter DG, Strathdee CA, et al. (2007) Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells. Apoptosis 12: 1465-1478.
63. Lu M, Strohecker A, Chen F, Kwan T, Bosman J, et al. (2008) Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin Cancer Res 14: 3168-3176.
64. Li F, Ling X, Huang H, Brattain L, Apontes P, et al. (2005) Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 24: 1385-1395.
65. Bhat UG, Gartel AL (2008) Differential sensitivity of human colon cancer cell lines to the nucleoside analogs ARC and DRB. Int J Cancer 122: 1426-1429.
66. Li F, Brattain MG (2006) Role of the Survivin gene in pathophysiology. Am J Pathol 169: 1-11.
67. Varfolomeev EE, Ashkenazi A (2004) Tumor necrosis factor: an apoptosis JuNKie? Cell 116: 491-497.
68. Yang D, Wang S, Brooks C, Dong Z, Schoenlein PV, et al. (2009) IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression. Cancer Res 69: 1080-1088.
69. Zimmerman M, Yang D, Hu X, Liu F, Singh N, et al. (2010) IFN-c Upregulates Survivin and Ifi202 Expression to Induce Survival and Proliferation of Tumor- Specific T Cells. PLoS One 5: e14076.
70. McGough JM, Yang D, Huang S, Georgi D, Hewitt SM, et al. (2008) DNA methylation represses IFN-c-induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells. Mol Cancer Res 6: 1841-1851.
71. Chao DT, Linette GP, Boise LH, White LS, Thompson CB, et al. (1995) Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 182: 821-828.
72. Yang D, Thangaraju M, Browning DD, Dong Z, Korchin B, et al. (2007) IFN Regulatory Factor 8 Mediates Apoptosis in Nonhemopoietic Tumor Cells via Regulation of Fas Expression. J Immunol 179: 4775-4782.
73. Yang D, Stewart TJ, Smith KK, Georgi D, Abrams SI, et al. (2008) Downregulation of IFN-cR in association with loss of Fas function is linked to tumor progression. Int J Cancer 122: 350-362.